Bruker Announces Acquisition of MOLECUBES NV
19 November 2021 - 11:00PM
Business Wire
Expands Nuclear Molecular Imaging Portfolio
with Modular Benchtop CUBES™ PET, SPECT and CT Preclinical
Imaging Systems
Bruker Corporation (Nasdaq: BRKR) today announced the
acquisition of MOLECUBES NV, a dynamic innovator in benchtop
preclinical nuclear molecular imaging (NMI) systems. This
acquisition strengthens Bruker’s position as a leading NMI
solutions provider in preclinical and translational imaging
research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211119005258/en/
Modular benchtop CUBES™ NMI systems of
MOLECUBES (Photo: Business Wire)
The combination of Bruker’s preclinical imaging products and
global footprint with the modular benchtop CUBES™ systems of
MOLECUBES will provide a broader NMI offering to further accelerate
worldwide adoption of preclinical NMI in academic medical centers
and biopharma companies.
Dr. Wulf I. Jung, President of the Bruker BioSpin Preclinical
Imaging Division commented: “Nuclear molecular preclinical and
translational imaging research are growing market segments, in
which we are already recognized for high-performance simultaneous
PET/MR and PET/SPECT/CT instruments, and for our PMOD™ PET data
analysis software. The acquisition of MOLECUBES adds scalable
benchtop instruments to our portfolio for serving the NMI
preclinical research community. The synergies between our and
MOLECUBES’ research and development, applications and service teams
is expected to benefit our combined NMI customers worldwide.”
Professor Roel Van Holen, CEO of MOLECUBES, added: “The
MOLECUBES vision has always centered around making in vivo NMI
available to every lab, by developing small footprint imagers
without compromising on image quality. The high throughput of our
unique scalable technology makes it an excellent tool to speed up
drug discovery and translational research. Bruker has the reach to
increase access to the CUBES in labs throughout the world, aligning
with our joint mission to support the quality and speed of
preclinical drug development and fundamental pathobiology research.
Our team is looking forward to working within Bruker on research
and innovative solutions for our existing and future
customers.”
As a fast-growing company founded in 2015 in Ghent, Belgium,
MOLECUBES develops and sells high-end PET, SPECT, and CT CUBES™
systems, with a global installated base of more than 70 systems
among key opinion leaders. The modular benchtop CUBES complement
Bruker’s integrated, floor-standing preclinical small animal
imaging systems.
MOLECUBES will remain an innovative and agile operational team
within the Bruker BioSpin Preclinical Imaging division, and
MOLECUBES customers can continue communications through existing
channels. MOLECUBES’ R&D and applications teams will
collaborate with Bruker’s preclinical imaging experts to
continuously advance NMI technology, software, workflows and
applications.
MOLECUBES generated approximately Euro 5 million in FY 2020
revenue. Financial details of the acquisition were not disclosed.
For more information, please visit
www.bruker.com/en/products-and-solutions/preclinical-imaging
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
About MOLECUBES
MOLECUBES in Ghent, Belgium is a manufacturer of molecular
imaging instrumentation for preclinical research. MOLECUBES offers
a modular benchtop platform, consisting of preclinical PET, SPECT
and CT CUBES™ imagers. The CUBES form a scalable platform, enabling
high throughput research with a compact footprint. MOLECUBES’
mission is to advance the imaging in preclinical settings with over
70 CUBES installed in leading research facilities within academic
institutions, research hospitals, and biopharma companies and
contract research organizations. www.molecubes.com
The CUBES are compact micro-CT, micro-SPECT and micro-PET
scanners for molecular small animal imaging, as standalone systems
or in modular combinations:
- β-CUBE – high-performance preclinical PET scanner
- X-CUBE – high-performance preclinical CT scanner
- γ-CUBE – high-performance preclinical SPECT scanner
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211119005258/en/
Bruker Investor Relations Contact T: +1 (978) 663–3660,
ext. 1479 E: Investor.Relations@bruker.com Media Contact
Thorsten Thiel, Ph.D. VP of Group Marketing Bruker BioSpin T: +49
(721) 5161-6500 E: pr@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024